Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ulviprubart - Abcuro

Next Previous
Drug Profile

Ulviprubart - Abcuro

Alternative Names: ABC-008; Anti-KLRG1 antibody - Abcuro

Latest Information Update: 11 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abcuro
  • Class Anti-inflammatories; Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; C-type lectin antagonists; Immunologic receptor antagonists; NK cell lectin-like receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inclusion body myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Inclusion body myositis
  • Phase I/II Large granular lymphocytic leukaemia
  • Preclinical Non-Hodgkin's lymphoma
  • No development reported Autoimmune disorders

Most Recent Events

  • 09 Dec 2025 Pharmacodynamics and adverse events data from a phase-I/II trial in Large granular lymphocytic leukaemia released by Abcuro
  • 03 Nov 2025 Ulviprubart - Abcuro receives Fast Track designation for Inclusion body myositis [SC,Injection] in USA
  • 28 Aug 2025 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top